NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.
CASRN: 1802558-87-7
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of avalglucosidase during breastfeeding. Avalglucosidase is a large protein molecule with a molecular weight of about 124,000 Da, so the amount in milk is likely to be very low and absorption is unlikely because it is probably partially destroyed in the infant's gastrointestinal tract and poorly absorbed orally. Because no published experience exists with avalglucosidase during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Substance Identification
Substance Name
Avalglucosidase Alfa
CAS Registry Number
1802558-87-7
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- LactMed App
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.[Neuromuscul Disord. 2019]Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.Pena LDM, Barohn RJ, Byrne BJ, Desnuelle C, Goker-Alpan O, Ladha S, Laforêt P, Mengel KE, Pestronk A, Pouget J, et al. Neuromuscul Disord. 2019 Mar; 29(3):167-186. Epub 2018 Dec 17.
- Review Avalglucosidase alfa: First Approval.[Drugs. 2021]Review Avalglucosidase alfa: First Approval.Dhillon S. Drugs. 2021 Oct; 81(15):1803-1809.
- Review Faricimab[Drugs and Lactation Database (...]Review Faricimab. Drugs and Lactation Database (LactMed). 2006
- Review Dornase Alfa[Drugs and Lactation Database (...]Review Dornase Alfa. Drugs and Lactation Database (LactMed). 2006
- Review Factor Xa (recombinant), Inactivated[Drugs and Lactation Database (...]Review Factor Xa (recombinant), Inactivated. Drugs and Lactation Database (LactMed). 2006
- Avalglucosidase Alfa - Drugs and Lactation Database (LactMed)Avalglucosidase Alfa - Drugs and Lactation Database (LactMed)
Your browsing activity is empty.
Activity recording is turned off.
See more...